Article
Influence of genetic polymorphisms in vascular endothelial-related genes on the clinical outcome of axitinib in patients with metastatic renal cell carcinoma.
Cancer biology & therapy - 31 Dec 2024
Numakura Kazuyuki, Igarashi Ryoma, Takahashi Makoto, Nara Taketoshi, Kanda Sohei, Saito Mitsuru, Narita Shintaro, Inoue Takamitsu, Niioka Takenori, Miura Masatomo, Habuchi Tomonori
Abstract excerpt
OBJECTIVE: Axitinib is an oral multi-target tyrosine kinase inhibitor used for the treatment of renal cell carcinoma (RCC). Because of the severe adverse events (AEs) associated with axitinib, patients often need dose reductions or discontinue its use, highlighting the need for effective biomarkers to assess efficacy and/or AEs. The aim of this study was to investigate the relationship between single nucleotide...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
